- An analysis of the National Cancer Database (NCDB) shows that lymph node dissection (LND) provides no survival benefit for patients with pancreatic neuroendocrine tumors (pNETs).
Why this matters
- Current guidelines recommend lymph node dissection in pNETs, but there is little evidence supporting this position.
- Retrospective analysis of the NCDB (n=2644).
- Funding: National Natural Science Foundation of China; Chinese Academy of Medical Sciences; Capital Health Research and Development of Special.
- An inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis revealed a similar median OS between LND and non-LND groups (152.8 vs 147.3 months; P=.61).
- The groups had similar OS:
- 5-year OS: 91.2% LND vs 89.5% non-LND.
- 10-year OS: 67.0% LND vs 72.0% non-LND.
- HR, 1.15; P=.18.
- Subgroup analyses by clinical T and N stages showed no survival benefit from LND.
- Among LND patients who had >9 lymph nodes removed vs ≤9, there was a similar median OS (136.2 vs 149.9 months; P=.55) and similar 5- and 10-year OS (>9; HR, 0.82; P=.22).
- Retrospective analysis.